Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.55 |
| ▸ | CA2 | P00918 | 11/20 | 0.55 |
| ▸ | CA12 | O43570 | 6/20 | 0.47 |
| ▸ | CA9 | Q16790 | 6/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | MMP9 | P14780 | 2/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2291440 | 0.87 | CA1 (0.51) | CA1CA2CA12CA9CA4 | |
| SCHEMBL791306 | 0.78 | CA2 (0.56) | CA1CA2CA12CA9EGFR | |
| SCHEMBL22771313 | 0.77 | CA1 (0.52) | CA1CA2CA12CA9MGLL | |
| SCHEMBL872557 | 0.77 | MGLL (0.47) | MGLL | |
| SCHEMBL17001563 | 0.77 | CA2 (0.55) | CA1CA2CA12CA9EGFR | |
| SCHEMBL16990184 | 0.76 | CA1 (0.54) | CA1CA2CA12CA9CA7 | |
| SCHEMBL487585 | 0.76 | CA1 (0.59) | CA1CA2CA12CA9 | |
| SCHEMBL6183257 | 0.76 | CA12 (0.66) | CA1CA2CA12CA9MGLL | |
| SCHEMBL25339171 | 0.74 | MEN1 (0.52) | CA1CA2CA12CA9CA4 | |
| SCHEMBL1619490 | 0.74 | CA1 (0.58) | CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008007-B2 | S-adenosyl-L-methionine analogs with extended activated groups for transfer by methyltransferases | RWTH AACHEN (DE) | 2011-08-30 | — | — | US | disclosed |
| US-20090018101-A1 | S-ADENOSYL-L-METHIONINE ANALOGS WITH EXTENDED ACTIVATED GROUPS FOR TRANSFER BY METHYLTRANSFERASES | RWTH AACHEN (DE) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018101-A1 | S-ADENOSYL-L-METHIONINE ANALOGS WITH EXTENDED ACTIVATED GROUPS FOR TRANSFER BY METHYLTRANSFERASES | BHMT2, MSRB3, PRMT3 | CA1 2302/4885CA2 2918/4885CA12 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.